HAEMONETICS CORP/MASS (HAE) Stock Fundamental Analysis
USA - NYSE:HAE - US4050241003 - Common Stock
49.68 USD
+0.42 (+0.85%)
HAE gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 191 industry peers in the Health Care Equipment & Supplies industry. HAE scores excellent on profitability, but there are some minor concerns on its financial health. HAE may be a bit undervalued, certainly considering the very reasonable score on growth
1. Profitability
1.1 Basic Checks
In the past year HAE was profitable.
HAE had a positive operating cash flow in the past year.
In the past 5 years HAE has always been profitable.
Each year in the past 5 years HAE had a positive operating cash flow.
1.2 Ratios
The Return On Assets of HAE (6.63%) is better than 87.43% of its industry peers.
Looking at the Return On Equity, with a value of 18.51%, HAE belongs to the top of the industry, outperforming 93.19% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 9.88%, HAE belongs to the top of the industry, outperforming 89.53% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for HAE is in line with the industry average of 9.00%.
The 3 year average ROIC (8.96%) for HAE is below the current ROIC(9.88%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.63% | ||
| ROE | 18.51% | ||
| ROIC | 9.88% |
ROA(3y)6.05%
ROA(5y)4.97%
ROE(3y)15.59%
ROE(5y)12.69%
ROIC(3y)8.96%
ROIC(5y)7.22%
1.3 Margins
The Profit Margin of HAE (12.13%) is better than 88.48% of its industry peers.
In the last couple of years the Profit Margin of HAE has grown nicely.
HAE's Operating Margin of 18.12% is amongst the best of the industry. HAE outperforms 89.01% of its industry peers.
In the last couple of years the Operating Margin of HAE has remained more or less at the same level.
Looking at the Gross Margin, with a value of 57.42%, HAE is in line with its industry, outperforming 56.54% of the companies in the same industry.
In the last couple of years the Gross Margin of HAE has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 18.12% | ||
| PM (TTM) | 12.13% | ||
| GM | 57.42% |
OM growth 3Y21.18%
OM growth 5Y0.48%
PM growth 3Y41.28%
PM growth 5Y9.75%
GM growth 3Y1.97%
GM growth 5Y2.6%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), HAE is creating some value.
Compared to 1 year ago, HAE has less shares outstanding
Compared to 5 years ago, HAE has less shares outstanding
HAE has a worse debt/assets ratio than last year.
2.2 Solvency
HAE has an Altman-Z score of 2.16. This is not the best score and indicates that HAE is in the grey zone with still only limited risk for bankruptcy at the moment.
The Altman-Z score of HAE (2.16) is better than 62.83% of its industry peers.
The Debt to FCF ratio of HAE is 7.62, which is on the high side as it means it would take HAE, 7.62 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of HAE (7.62) is better than 75.92% of its industry peers.
A Debt/Equity ratio of 1.04 is on the high side and indicates that HAE has dependencies on debt financing.
HAE has a worse Debt to Equity ratio (1.04) than 77.49% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.04 | ||
| Debt/FCF | 7.62 | ||
| Altman-Z | 2.16 |
ROIC/WACC1.51
WACC6.56%
2.3 Liquidity
HAE has a Current Ratio of 1.72. This is a normal value and indicates that HAE is financially healthy and should not expect problems in meeting its short term obligations.
HAE's Current ratio of 1.72 is on the low side compared to the rest of the industry. HAE is outperformed by 69.63% of its industry peers.
A Quick Ratio of 1.04 indicates that HAE should not have too much problems paying its short term obligations.
HAE has a Quick ratio of 1.04. This is in the lower half of the industry: HAE underperforms 74.87% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.72 | ||
| Quick Ratio | 1.04 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 17.72% over the past year.
Measured over the past 5 years, HAE shows a small growth in Earnings Per Share. The EPS has been growing by 6.66% on average per year.
HAE shows a small growth in Revenue. In the last year, the Revenue has grown by 0.91%.
The Revenue has been growing slightly by 6.60% on average over the past years.
EPS 1Y (TTM)17.72%
EPS 3Y20.84%
EPS 5Y6.66%
EPS Q2Q%7.84%
Revenue 1Y (TTM)0.91%
Revenue growth 3Y11.07%
Revenue growth 5Y6.6%
Sales Q2Q%-4.4%
3.2 Future
Based on estimates for the next years, HAE will show a quite strong growth in Earnings Per Share. The EPS will grow by 10.55% on average per year.
Based on estimates for the next years, HAE will show a small growth in Revenue. The Revenue will grow by 2.86% on average per year.
EPS Next Y6.64%
EPS Next 2Y10.13%
EPS Next 3Y10.55%
EPS Next 5YN/A
Revenue Next Year-4.73%
Revenue Next 2Y0.69%
Revenue Next 3Y2.86%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 10.68, which indicates a very decent valuation of HAE.
92.15% of the companies in the same industry are more expensive than HAE, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 27.76, HAE is valued rather cheaply.
The Price/Forward Earnings ratio is 8.96, which indicates a very decent valuation of HAE.
HAE's Price/Forward Earnings ratio is rather cheap when compared to the industry. HAE is cheaper than 94.24% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 23.21. HAE is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.68 | ||
| Fwd PE | 8.96 |
4.2 Price Multiples
HAE's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. HAE is cheaper than 92.15% of the companies in the same industry.
HAE's Price/Free Cash Flow ratio is rather cheap when compared to the industry. HAE is cheaper than 93.19% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 14.89 | ||
| EV/EBITDA | 9.21 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
The excellent profitability rating of HAE may justify a higher PE ratio.
PEG (NY)1.61
PEG (5Y)1.6
EPS Next 2Y10.13%
EPS Next 3Y10.55%
5. Dividend
5.1 Amount
HAE does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NYSE:HAE (10/8/2025, 10:09:35 AM)
49.68
+0.42 (+0.85%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners115.71%
Inst Owner Change0%
Ins Owners1.14%
Ins Owner Change9.02%
Market Cap2.39B
Analysts81.33
Price Target81.91 (64.88%)
Short Float %7.13%
Short Ratio3.12
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.91%
Min EPS beat(2)0.62%
Max EPS beat(2)7.2%
EPS beat(4)4
Avg EPS beat(4)2.96%
Min EPS beat(4)0.62%
Max EPS beat(4)7.2%
EPS beat(8)7
Avg EPS beat(8)4%
EPS beat(12)11
Avg EPS beat(12)9.1%
EPS beat(16)14
Avg EPS beat(16)8.76%
Revenue beat(2)1
Avg Revenue beat(2)1.96%
Min Revenue beat(2)-0.63%
Max Revenue beat(2)4.55%
Revenue beat(4)1
Avg Revenue beat(4)0.38%
Min Revenue beat(4)-2.22%
Max Revenue beat(4)4.55%
Revenue beat(8)4
Avg Revenue beat(8)1.08%
Revenue beat(12)8
Avg Revenue beat(12)2.33%
Revenue beat(16)10
Avg Revenue beat(16)1.82%
PT rev (1m)0%
PT rev (3m)-12.51%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-5.46%
EPS NY rev (1m)0.02%
EPS NY rev (3m)-0.93%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.89%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.21%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.68 | ||
| Fwd PE | 8.96 | ||
| P/S | 1.78 | ||
| P/FCF | 14.89 | ||
| P/OCF | 10.57 | ||
| P/B | 2.71 | ||
| P/tB | N/A | ||
| EV/EBITDA | 9.21 |
EPS(TTM)4.65
EY9.36%
EPS(NY)5.54
Fwd EY11.16%
FCF(TTM)3.34
FCFY6.72%
OCF(TTM)4.7
OCFY9.46%
SpS27.94
BVpS18.31
TBVpS-3.65
PEG (NY)1.61
PEG (5Y)1.6
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.63% | ||
| ROE | 18.51% | ||
| ROCE | 12.63% | ||
| ROIC | 9.88% | ||
| ROICexc | 11.65% | ||
| ROICexgc | 32.9% | ||
| OM | 18.12% | ||
| PM (TTM) | 12.13% | ||
| GM | 57.42% | ||
| FCFM | 11.95% |
ROA(3y)6.05%
ROA(5y)4.97%
ROE(3y)15.59%
ROE(5y)12.69%
ROIC(3y)8.96%
ROIC(5y)7.22%
ROICexc(3y)10.46%
ROICexc(5y)8.47%
ROICexgc(3y)26.78%
ROICexgc(5y)22.33%
ROCE(3y)11.45%
ROCE(5y)9.23%
ROICexcg growth 3Y22.36%
ROICexcg growth 5Y7.33%
ROICexc growth 3Y21.7%
ROICexc growth 5Y-5.09%
OM growth 3Y21.18%
OM growth 5Y0.48%
PM growth 3Y41.28%
PM growth 5Y9.75%
GM growth 3Y1.97%
GM growth 5Y2.6%
F-Score8
Asset Turnover0.55
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.04 | ||
| Debt/FCF | 7.62 | ||
| Debt/EBITDA | 2.56 | ||
| Cap/Depr | 57.06% | ||
| Cap/Sales | 4.88% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 63.09% | ||
| Profit Quality | 98.45% | ||
| Current Ratio | 1.72 | ||
| Quick Ratio | 1.04 | ||
| Altman-Z | 2.16 |
F-Score8
WACC6.56%
ROIC/WACC1.51
Cap/Depr(3y)79.52%
Cap/Depr(5y)76.24%
Cap/Sales(3y)6.31%
Cap/Sales(5y)6.58%
Profit Quality(3y)103.91%
Profit Quality(5y)115.34%
High Growth Momentum
Growth
EPS 1Y (TTM)17.72%
EPS 3Y20.84%
EPS 5Y6.66%
EPS Q2Q%7.84%
EPS Next Y6.64%
EPS Next 2Y10.13%
EPS Next 3Y10.55%
EPS Next 5YN/A
Revenue 1Y (TTM)0.91%
Revenue growth 3Y11.07%
Revenue growth 5Y6.6%
Sales Q2Q%-4.4%
Revenue Next Year-4.73%
Revenue Next 2Y0.69%
Revenue Next 3Y2.86%
Revenue Next 5YN/A
EBIT growth 1Y18.51%
EBIT growth 3Y34.59%
EBIT growth 5Y7.12%
EBIT Next Year30.67%
EBIT Next 3Y15.63%
EBIT Next 5YN/A
FCF growth 1Y-8.53%
FCF growth 3Y16.98%
FCF growth 5Y2.09%
OCF growth 1Y-9.46%
OCF growth 3Y1.79%
OCF growth 5Y2.81%